跳至主要内容
临床试验/NCT04348448
NCT04348448终止不适用

Observational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 Pneumonia

AUSL Romagna Rimini1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2020年2月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
终止
发起方
入组人数
100
试验地点
1
主要终点
intensive care treatment

研究概览

简要总结

The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with COVID 19 who have received or are candidates to receive treatment with canakinumab subcutaneously
  • Age> 18 years
  • Pneumonia diagnosed with Chest X-ray / or Chest CT

排除标准

  • Patients with Covid19-related pathology in the context of another cause of major admission (trauma, surgery)

结局指标

主要结局

intensive care treatment

时间窗: 9 months

percentage of patients treated with canakinumab sc who do not require intensive care treatment during hospitalization for COVID-19

次要结局

  • % died after 1 month after treatment(9 months)
  • ICU stay times(9 months)
  • hospitalization(9 months)
  • adverse event(9 months)

研究者

发起方
AUSL Romagna Rimini
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验